

Index

- Abel, R. 57
'abusus' rights 250, 264, 265, 268
Accelerating Access Initiative (AAI)
86, 90–91
Adams, J.D. 208
aeronautical engineering 34, 38
Africa Group of the TRIPS Council
76
Agrawal, A. 25
agricultural technology 38, 40
AIDS/HIV 4–5, 70–105
 generic producers and supply-side
 competition in reduced-cost
 ARVs 98–9
 scale of pandemic in Sub-Saharan
 Africa 84–6
 supply of anti-retroviral drugs in
 Sub-Saharan Africa 84–98
Air Pirates comic books 58
Albright, B. 217
ambiguity
 of measurements 260–61
 of patent claims 229, 235
Andersen, B. 112, 114, 117, 129, 132
antibodies 33–4, 35, 41
anti-competition costs 122–3
antigen 33–4
anti-patent movement 315
anti-retroviral drugs (ARVs) 71, 74–5,
84–101
 key role of generic producers and
 supply-side competition in
 reduced-cost ARVs 98–9
 supply in Sub-Saharan Africa
 84–98
 AAI 86, 90–91
 ARVs patented in OAPI zone
 97–8
 current situation and future
 prospects 94–8
 Indian generic supply 86–7, 91–3,
 98, 100
 supply of patented drugs 87–90,
 92, 93
AOL 50
applied sciences 23–4
appropriability
 problem of 118–20
 reasons to not patent 154, 156,
 166–7, 168
arbitrary technological trajectories 122
Arora, A. 32–3, 323
Arrow, K.J. 72, 118–19, 120, 127, 128,
134, 182–3, 184, 185
Arthur, B. 126, 129
Arundel, A. 120, 150–51, 192
Ashdown v. Telegraph Group 64
assignability of copyright interest 48,
60–61
Atkinson, R. 40
Atomic Energy Commission (UK) 27
Attaran, A. 98
Audretsch, D.B. 151
Aurobindo 93
Australia 63
 contemporary music industry 50–51,
 55–6
authorization management 264, 265,
268
authors' rights management societies
260
awareness of IPR 197, 199, 204, 206
backward citations 231, 232
Bacon, F. 26
Balconi, M. 284
Bangui Agreement 4, 78–84
 Revised 78, 82–4, 100
Bansee, L. 91
bar coding patents 217, 220
Bar-Shalom, A. 33–4, 41

- bargaining 121
 complexity of bargain agreements
 135–6
 Barzel, Y. 248
 ‘basicness’ of inventions/technology
 233, 235–6
 Bayh-Dole Act 1980 (US) 2–3, 110, 332
 reforming 40–42
 universities and patenting 29, 37, 39,
 121, 137, 330
 Bell Laboratories 23, 316
 Bentham, J. 113, 117, 131
 Bently, L. 60, 62
 Bernal, J.D. 26, 27
 Berne Convention for the Protection
 of Literacy and Artistic Works
 61, 244
 Bertin, G.Y. 152, 153, 154, 159
 Bessen, J. 269
 Bessy, C. 251, 259, 267, 269
 Bettig, R. 49–50, 51
 bibliographic coupling 282–3
 bio-piracy 132
 biotechnology 39
 small high-tech firms and patenting
 150, 157–70, 170–71, 172
 Blakeney, M. 47, 61
 blanket licences 273
 blocking patents 122–3, 128–9
 small high-tech firms 152, 159, 162,
 163
 BMG 50
 Bok, D. 37, 40
 Bonacich, P. 295
 Brazil 74, 86, 87, 90
 Breschi, S. 183, 284
 Bristol-Myers 88, 89
 brokers of new technology 296–301,
 302
 Brousseau, E. 246, 247, 249, 251, 256,
 267, 269
 Burchfiel, K. 227
 Burkina Faso 88, 91
 Burundi 88
 Bush, V. 18, 26–7, 28
 business services 191
 Business Software Alliance 260
 Campbell, D. 24
Campbell v. Acuff-Rose Music, Inc. 62
 capital, attracting from external
 investors 153–4, 161–2, 163
 capitalism 17, 21–2
 intellectual capitalism 315–17
 Capling, A. 50, 55, 55–6
 catch-up 326
 CBS 50
 CBS/Fox 51
 cell biology 20
 Centre for Research on Innovation and
 Internationalization (CESPRI)
 291
 Chateauraynaud, F. 259
 Chayes, A. 55
 chemical engineering 23, 38
 chemical patents 231, 234
 Cheung, S. 116, 130
 China 325
 Christensen, J.L. 136, 181, 186
 CIC Video 51
 Cipla 93, 94, 100
 citation networks 279
 networks of organizations 282,
 286–7, 288, 291
 networks of patents 281–2
 semiconductor and computer
 industries 293–301
 citations of published works 330–31
 civil engineering 23
 Clark, J.B. 117
 clearing house, international 64, 322
 co-authorship 282, 283–4, 285
 co-citation networks 279
 networks of organizations 282,
 287–91
 networks of patents 282, 283
 semiconductor and computer
 industries 292, 293–301
 codified knowledge 184, 187, 199
 Cohen, W. 25, 32–3, 38, 116, 120, 129,
 155, 162, 185, 225
 Cohen-Boyer gene-splitting process 39
 collective governance *see* private
 institutions
 Columbia Pictures Entertainment 50
 Columbia Tri-Star Home Video 51
 Colyvas, J. 39
 Comanor, W.S. 226, 227
 combustion engines 224–5
 Comcast Inc. 50, 63

- commodification of creativity 46–9
 limiting 60–61
 ‘common procedure’ 82, 100
 commons
 global 2–5
 loss of and copyright 57–9
 scientific 2–3, 17–45
 protecting 32–42
 communication 182–3
 communitarianism 30
 comparative institutional analysis
 243–77
 competence building 205–8
 competition 22
 innovation-enhanced 127–30, 141
 publicly supported research and
 private research 31
 supply-side 98–9
 competition law 64
 complex industries 150
 compulsory licensing 75–6, 77, 124,
 128–9, 255
 Bangui Agreement 81
 Revised Agreement 83–4
 Computer and Communication
 Industry Association (CCIA) 7
 computer industry 291–301, 302,
 303–5
 computer science 24, 34
 concentration 49–51
Conference on Patent Policy Making 7
 contextual patent strategies 171–2
 continuation patents 8–9, 12, 215–39
 descriptive statistics within sectors
 224–30
 determinants of continuation
 application practice 230–34
 practice under US patent law 219–23
 changes in patent law 221–2
 patentees’ use of procedure 222–3
 contracts and contracting 12, 248, 321
 control of actual uses of authorized
 uses 264, 265, 268
 Cook-Deegan, R. 33–4, 41
 Coombe, R. 58–9
 Cooper, C. 267
 cooperation, legal basis for 152–3, 160,
 163
 coordinating institutions 9–11
 coordination 321–2
 coordination devices 247–8
 co-patenting 282, 286
 Copyleft 52
 copyright 3–4, 46–69
 acquisition of private power 49–55
 commodification of creativity 46–9
 limiting 60–61
 compared with patents 260–61,
 268–9
 counterbalancing rights 61–2
 current debates 14
 and development 59–60
 fair use/fair dealing rights 53, 59,
 62–3
 holistic thinking 64
 public and private institutions 9,
 243–77
 public interest right 63–4
 significance of private power 55–60
 traditional cultural expressions 132
 Coriat, B. 74, 120
 Corley, Eric 52–3
 corporate dominance 3–4, 46–69
 acquisition of private power 49–55
 significance of private power 55–60
 corporate innovation systems 324–5,
 327–9
 corporate law 64
 corporate strategies 128–30
 costs
 administration 122
 costs of applying and maintaining
 patent too high 155, 164
 enforcement 122, 154, 155–6
 governance and maladaptation
 247–8
 information costs 256–7
 monopoly costs 122–3
 transaction costs *see* transaction
 costs
 counterbalancing rights 61–2
 courts in charge of patent
 infringements 266–7
 creativity
 commodification of 46–9, 60–61
 economic rationale of organizing
 133–9, 141
 incentives to be creative 117–24
 Crixivan 88, 89
 cross-licensing 125

- crowding, technological 279, 293, 294–301
- Crown Cork & Seal Co. v. Gutmann Co.* 220
- culture 2, 3–4
- filtering and homogenization 55–7
 - fundamental approach 59–60
 - symbols and dialogue 58–9
 - traditional cultural expressions 132
- Danish Patent and Trademark Office (DKPTO) 7–8, 179–214
- in Danish innovation system 190–92
 - functions 190–92
 - general effects on knowledge
 - transfer and competence building 205–8
 - knowledge diffusion from patenting process 192–205
 - importance of domestic location 201–4
 - potential effects of knowledge flows from DKPTO 196–201
- David, P. 125–6, 127, 129, 135, 326
- Davis, L. 115
- decentralization 318–21
- DeCSS (Decrypted Content Scrambling System) source code 52–3
- Defense Advanced Research Projects Agency (DARPA) 316
- delay 219–20
- Demaine, L. 35
- Denmark 172–3
- small high-tech firms and patenting 151, 157–70
- Department of Defense (US) 27
- design of IPR system 11–12, 142
- detection of infringements 7, 154, 156, 165, 168, 264, 265, 268
- developing countries 4–5, 70–105
- development
- copyright and 59–60
 - level of and access to drugs before TRIPS 74
 - patent system and catch-up 326
- development rights 10, 130
- diffusion 136, 253, 280–81
- diverse policies 259, 262–3
 - from patenting process 192–205
- digital rights management (DRM) systems 256–7, 322
- direct citation links 281–2
- disclosure
- incentives to disclose 133–8, 317, 319
 - problem 119
 - role of patent information disclosure for governance 322–3
- discrete industries 150
- disinterestedness 30
- Disney Corporation 50, 51, 58, 65
- distributed innovation processes 114–15
- distributed intellectual capital management 322
- distribution rights 48, 49–55, 60–61
- diversion of activity 122
- Doha Declaration (2001) 76–8, 100–101
- dot.com bubble 121
- Dreyfuss, R. 36, 42
- Droit d'Auteur* 244, 245, 252, 270, 271
- drugs *see* pharmaceuticals/drugs
- Dumoulin, J. 87, 88
- duration
- copyright protection 48, 59, 60–61
 - patents 81–2, 83
- DVDs 52–3
- dynamic efficiency argument 125
- economic hold-up 217
- economies of scale 254
- economies of scope 254
- efficiency 125–7
- Eisenberg, R. 29, 31, 32, 41
- Eldred v. Ashcroft* 61, 63
- electrical engineering 24, 38
- electrical patents 231, 234
- electronic self-publishing 57, 67
- emerging industries 316–17, 327
- EMI 50
- enforcement
- problems and patenting 154, 155–6, 165–6, 168
 - public and private institutions 246–7, 248–50, 268, 269
 - incomplete IPRs 251, 252
 - prohibition of use 263
 - public vs private governance trade-off 264, 265
- see also* infringements

- enforcement costs 122, 154, 155–6
 engineering 23–4, 38
 entrepreneurial talent, market
 protection of 130–33
 entropy index 293–4
 Epirivir 88, 89
 European Patent Convention (EPC)
 180
 European Patent Office (EPO) 180,
 189, 203–4, 206–8, 291
 European Research Area (ERA) 333
 European Union (formerly European
 Community) (EU) 61, 110
 EU companies and knowledge
 networks 297, 298, 299, 302
 harmonized patent system 189–90,
 206–8
 military innovation system 333
 evolution of IPR system 313–17
 evolutionary processes 21–5
ex officio licences 81, 83–4
 exclusion 263, 264, 265, 268
 expertise 267
 externalities 28
- fair use/fair dealing rights 53, 59, 62–3
 Fares, M. 247
 fees *see* licensing; revenue collection;
 royalties
 Feldman, M.P. 184–5, 191
 Fellmeth, A. 35
 Festival 50
 filing date 221
 Film Council (UK) Digital Screen
 Network 56–7
 film sharing software 53–4
 films and filmed entertainment 51–2,
 52–4
 cultural filtering 56–7
 performers' rights 61–2
 filtering, cultural 55–7
 firm
 age 194–5, 201
 size 194, 203, 204
 first-line treatments 94, 97
 fixed-dose bitherapies 94, 96
 fixed-dose tritherapies 92, 94, 96, 99
 followers, technological 297, 298–301,
 302
 Foray, D. 186, 244
- Ford Motor Company v. Jerome
 Lemelson* 215–16
 formal rules 247
 forward citations 231, 232
 Foundation for a Free Information
 Infrastructure (FFII) 7
 Fourth Estate 57
 FoxVideo 51
 France 245, 252
 IPR system compared with US's
 266–70
 SACEM 257, 258, 261, 266, 272–3,
 274
 free speech 53
 free trade 131–2
 Freeman, C. 324
 French Union 79
 'fructus' rights 250, 264, 265, 268
- Gaines, J. 59, 60
 gamesmanship, patent 216–18
 General Agreement on Tariffs and
 Trade (GATT) 47, 221, 244
*General Talking Pictures Corp. v.
 Western Electric Co.* 220
 generality of a patent 231, 233
 generic drugs 74, 100
 Bangui Agreement 80–81
 Revised Agreement 82–3, 84
 supply of ARVs in Sub-Saharan
 Africa 86–7
 current situation and future
 prospects 94–8
 Indian generic supply 86–7, 91–3,
 98, 100
 key role of generic producers in
 reduced-cost ARVs 98–9
 pharmaceutical companies and
 TRIPS 89
 generic institutions 266–8
 geographically mediated spillovers
 184–5
 germ theory of disease 23
 Gillespie-White, L. 98
 Glaxo 88, 89
 Glazier, S. 162
 global commons 2–5
 global dominance 49–55
 global rights 49–55
Godfrey v. Eames 220

- governance 335
 coordinating institutions 9–11
 economic rationales for a patent system 318–23
 patents as a governance mechanism 321–2
 property approach in a governance perspective 318–21
 role of patent information disclosure for governance 322–3
 governing institutions 11–14
 innovation systems *see* innovation systems
 public and private institutions 9, 243–77
 analytical framework 246–8
 incomplete setting of IPRs by public institutions 249, 250–53
 private institutions trade-off 253–65
 public vs private governance trade-off 263–5
 settling IPRs 248–50
 specialized and generic institutions 266–8
 of public science 20–21, 26–32
 GPO 93
 Grabowski, H. 227
 Graham, S.J.H. 229, 236
 Granstrand, O. 129, 316, 322
 Greece 325
 Gregersen, B. 189–90
 Griliches, Z. 230, 231
 Guennif, S. 89
 Guinea 88
 Guston, D. 26
 Gutterman, A. 317
 Hagedoorn, J. 286
 Hall, B. 230, 231, 233, 235
 Hannan, M. 287
 Hansen, M. 184
 Harabi, N. 155
 Harhoff, D. 227
 harmonized patent system 189–90, 206–8
 HarperCollins (UK) 57
 Hart, D. 26
 Hasenzahl, C. 75
 Hausman, J. 230, 231
 Hayakawa 57
 head-start profit 116–17
 healthcare 2, 4–5, 26–7
see also AIDS/HIV
 Heller, M. 32
 Henderson, R. 25, 183, 233
 Herfindahl-Hirschman concentration index 231, 233
 Hetero 93, 94, 100
 Highly Active Anti-retroviral Combination Therapies (HAART) 74–5, 87, 94
 Hobbes T. 113
 Holland 325
 homogenization, cultural 55–7
 human genome 31
 hybrid seed revolution 38
Hyde Park v. Yelland 63
 IBM 153
 IFO 151, 155, 164
 imitation
 high barriers to 136
 problems relating to preventing 154, 155, 164–5, 168
 protection against 151–2, 159, 163
 inborn inventive activity 118
 incentives
 to disclose 133–8, 317, 319
 economic incentive rationales 117–27, 141
 efficient resource allocation and use 125–7
 to innovate 117–24, 317, 319
 to invent 117–24, 317, 319
 incomplete IPRs 249, 250–53
 Indian generic ARV drugs 86–7, 91–3, 98, 100
 indicators of value 152, 153–4, 161–2, 163
 indirect citation links 281–2
 indivisibility 118–20
 industrial development from patents 127–33, 141
 industrialization 325
 information
 asymmetries 222

- rationale of increased information 138–9
 revealing too much in patent application 155, 165
 spillovers *see* spillovers
 suitability of patents and 154, 156, 166, 168
 information and communication technologies (ICTs) 256–7
 integration of military and civilian ICT systems 333
 IPRs and emergence of 316–17
 information costs 256–7
 information disclosure *see* disclosure
 infringements
 courts in charge of 266–7
 detecting 7, 154, 156, 165, 168, 264, 265, 268
 problems relating to patent infringement 154, 155–6, 165–6, 168, 172
 various modes of 259–60
 see also enforcement
 innovation 11–14, 335
 incentives to innovate 117–24, 317, 319
 innovation-enhanced competition 127–30, 141
 innovation intensity 195–6, 200, 205
 innovation systems 10–11, 186, 311–43
 corporate 324–5, 327–9
 emergence of 315–16
 evolution of IPR system and 313–17
 innovation systems approach and its rationales 323–5
 IPRs in 323–33
 military 324, 332–3
 national *see* national innovation systems
 sectoral 324, 326–7
 university 324, 329–32
 innovator's head-start profit 116–17
 Institut National Français de la Propriété Industrielle (INPI) 79
 institutional environment 11–14
 institutional infrastructure 189
 institutional organizations 246–7
 intangible assets, nature of 259, 260–62
 integrated innovation and diffusion processes 318, 319
 intellectual capitalism 315–17
 intellectual property (IP) regimes 313, 335
 intellectual capitalism and 315–16, 317
 interindividual governance structures (IGS) 247–8
 international agreements, hierarchy of 99–100
 international clearing house 64, 322
 International Intellectual Property Alliance 47
 Internet 316
 inter-organizational collaborations 322, 329
 'inventing around' patents by competitors 155, 164, 170
 invention
 accidental 118
 diffusion 136
 incentives to invent 117–24, 317, 319
 social origin of inventions 114–15
 invention privileges 314
 inventors, networks of 282, 283–4, 285
 isolated organizations 297, 298–301, 302
 issue date 223
 Ivory Coast 88
 Jaffe, A.B. 138, 183, 233, 281
 Japan 325, 326
 companies and knowledge networks 297, 298, 299, 302
 Jobard, J.-B.-A.-M. 112
 Johnson, B. 189–90
 joint innovation/diffusion incentive 318, 319
 joint patenting (co-patenting) 282, 286
 joint ventures 120–21
 Judson, H. 30–31
 Kaufer, E. 111, 314
 Kelley, D.J. 151
 Kilgore, H. 27
 Kingston, W. 124
 Kitch, E. 131
 Kitcher, P. 24
 Kleinknecht, A. 186
 Klevorick, A. 25
 Kline, D. 122, 123, 129, 153, 154

- knowledge 181–2
 diffusion/flows *see* diffusion
 dual nature and transformation of 187
 traditional 132
 transmission of 182–6, 199, 205–8
 knowledge based economy 316–17
 knowledge externalities 186
 knowledge institutions
 interaction with firms and potential learning processes 181–90
 see also universities
 knowledge networks 9–10, 278–310
 semiconductor and computer industries 291–301
 data sources 291–2
 positioning companies in the knowledge networks 293–301
 sample coverage 292–3, 303–5
 using patent citations to explore 280–91
 networks of inventors 282, 283–4, 285
 networks of organizations 282, 284–91
 networks of patents 281–3
 knowledge spillovers *see* spillovers
 Kortum, S. 224
 Kristensen, P. 184

 Lamivudine 89, 94, 95, 96, 97
 Lanjouw, J. 155, 172
 lead time advantages 193
 leaders, technological 296–301, 302
 leading edge industries 316–17, 327
 learning
 benefits from collectivization 254
 from interaction with DKPTO 196–201
 learning processes from interaction between knowledge institutions and firms 181–90
 Lefebvre, E. 151
 Lefebvre, L.A. 151
 legal basis for cooperation 152–3, 160, 163
 Lemelson, Jerome 215–16, 216–18, 234
 Lemley, M. 221, 256
 Lerner, J. 224
 less developed countries (LDCs) 4–5, 70–105
 Lessig, L. 256
 Levin, R. 25, 116, 120
 Levin, T.C. 150, 155
 Levinthal, D. 185
 libraries 134
 Libreville Agreement 79–80
 licensing 12, 321–2
 compulsory *see* compulsory licensing
 corporate innovation systems 328–9
 DRM systems 256–7, 322
 economic hold-up 217
 open source 269, 322, 329
 patents as legal basis for cooperation 152–3, 160, 163
 universities and licensing widely 39–42
 see also revenue collection
 Lissoni, F. 183, 284
 location of patent office 201–4, 205
 lock in 129–30
 Locke, J. 112
 Lopinavir 97
 Lucchini, S. 90, 91
 Lundvall, B.Å. 185, 244

 M-form of organization 320–21
 Machlup, F. 111, 114, 121, 135–6, 315, 317
 Macmillan, F. 46, 48, 49, 52, 63
 Macmillan Patfield, F. 55
Madey v. Duke 36
 maladaptation costs 248
 Malerba, F. 332
 Mali 88
 Mansfield, E. 116, 120
 ‘market protection of entrepreneurial talent’ rationale 130–33, 141
 Maskin, E. 269
 Matsushita Electric Industrial Company 50
 Maville, G. 87, 88
 Maxwell’s theory of electromagnetism 23
 May, C. 114
 Mazzoleni, R. 111, 112, 137, 317
 MCA 50
 MCA/Universal Home Video 51

- measurement 248–50, 268–9
 ambiguity of 260–61
 public institutions and incomplete 251, 252
 public vs private governance trade-off 264–5
 mechanical engineering 231, 234
 media law 64
 medical schools 38
 Meeus, M.T.M. 187
 Merck 88, 89
 mergers and acquisitions 49–50
 Merges, R. 114, 124, 128–9, 219
 Merton, R. 18, 30
 metallurgy 23
Metro-Goldwyn-Mayer Studios Inc. v. Grokster Ltd 53–4
 M’Fuka, C. 89
 military innovation systems 324, 332–3
 military research 137–8
 Mill, J.S. 117
 mining 314
 mission-oriented agencies 27
 mobile telephony 316
 Moge, M.E. 151
 Molas-Gallart, J. 138
 molecular biology 39
 monautopoly 112–13
 monoclonal antibodies 33–4
 monopolistic pricing 320
 monopoly costs 122–3
 monopoly profits, pre-invention 126–7
 moral rationales 112–17, 141
 moral rights 61–2
 Morkel, A. 151
 Morpheus software 53–4
 motor-generator technologies 224–5
 Mowery, D. 38, 229, 316
 MP3 files 52
 Murdoch, R. 57
 music 52, 256
 Australian music industry 50–51, 55–6
 infringements 260, 262
 US royalty collection societies 258
 Nasdaq 110, 120
 national emergency 77
 national innovation systems 324, 325–6
 Danish innovation system
 DKPTO in 190–92
 as a framework for learning processes 187–90
 National Institutes of Health (NIH) (US) 27, 41
 National Research Council (US) 32
 National Science Foundation (US) 27
 national security 26–7
 natural phenomena 33, 35
 natural rights 112–17, 141
 ‘nature of ideas’ argument 127–30
 negative binomial regression 230–34
 negative R&D results 323
 negotiating position, strengthening 153, 161
 Nelfinavir 97
 Nelson, R. 25, 31, 111, 112, 114, 124, 128–9, 137, 317
 Netanel, N.W. 63
 networks, knowledge *see* knowledge networks
 Nevirapine 94, 95, 96, 97
 new institutional economics (NIE) 11, 243–77
 News Corporation Ltd 50
 niche overlap 289, 293–4, 300–301
 Niger 88
 ‘no foreign application’ loophole 236
 nongovernmental organisations 78
 ‘non-rivalrous in use’ 28–9
 North, D. 118, 244, 246, 248, 249, 250, 325, 326
 novel technological ideas 115–16
 OECD 110
 Office Africain et Malgache de Propriété Industrielle (OAMPI) 79
 Olsen, T. 126, 127, 135
 open science 18–19, 25, 30–32
 public support of 20–21, 26–32
 open source licensing 269, 322, 329
 Oppenländer, K.H. 152, 159
 opportunity costs
 of depriving inventors of what they had before 123
 in depriving others from using most efficient solution 123
 of investment in arbitrary technological trajectories 122

- Orbital Engine Corporation 151
 order 138–9
 Organisation Africaine de la Propriété
 Intellectuelle (OAPI) 78–84,
 99–100
 organizing science, technology and
 creativity 133–9, 141
 organization theory 320–21
 organizations, networks of 282, 284–91
 organized scepticism 30
 originality of a patent 231, 233
 Orsi, F. 74, 120
 overdispersion 230
 owner behaviour 259, 262–3
- parallel imports 50–51
 Paramount 51
 Paris, T. 257
 Paris Convention for the Protection of
 Industrial Property 73, 79, 244
*Parke-Davis & Co. v. H. K. Mulford &
 Co.* 33
 Pasteur's quadrant 20, 24
 Patel, P. 324
 patent agents 191
 patent application process 172–3
 guidance 198, 199
 problems associated with 154, 155,
 162–4, 168
 patent blocking *see* blocking patents
 patent citations 9–10, 278–310
 using to explore knowledge
 networks 280–91
 patent code of 1474 314
 Patent Cooperation Treaty (PCT) 236
 patent demotivations 154–6, 162–7,
 168, 172
 nature of information 154, 156, 166,
 168
 other strategies of appropriability
 154, 156, 166–7, 168
 problems associated with application
 process 154, 155, 162–4, 168
 problems relating to patent
 infringement 154, 155–6, 165–6,
 168, 172
 problems relating to preventing
 imitation 154, 155, 164–5, 168
 patent engineers 191
 patent examiners 219, 267
- patent information analysts 322
 patent intelligence 172
 patent intensity 200
 patent litigation insurance 172
 patent motivations 151–4, 159–62, 163,
 167–70, 170–72
 indicators of value 152, 153–4,
 161–2, 163
 legal basis for cooperation 152–3,
 160, 163
 protection against imitation 151–2,
 159, 163
 strategic signals 152, 153, 160–61,
 163, 171
- patent offices 136–7, 180, 188, 266
 functions 190–92
 harmonized patent system 207–8
 importance of national patent
 offices 201–4, 205
 knowledge spillover 136–7
 from Danish office 7–8, 12,
 179–214
 US 8–9, 208, 215–39
- patent panic, cost of 124
 patent scope 33–4, 35
 problem of 128–30
 welfare cost of broad patent scope
 124
- patent term 218, 221, 222
 pharmaceuticals and 226–7
 patent walls 122–3
 patentability 155, 162–4, 168, 172
 patents and patenting 315
 Bangui Agreement 78–82
 comparison with copyright 260–61,
 268–9
 comparison with publishing 330–31
 current issues 13–14
 drug patenting 72–3
 early history 313–14
 economic rationales for a patent
 system 317–23
 patents as a governance
 mechanism 321–2
 role of patent information
 disclosure for governance
 322–3
 incentive rationale 119–20
 industrial development from 127–33,

- networks of 281–3
- patent system and losses to inventors 115
- performance of patenting process 7–9
- public and private institutions 9, 243–77
- science and patenting 2–3, 29–30, 31, 32–3
 - protection of scientific commons by patent law 33–7
- small high-tech firms *see* small high-tech firms
- social benefits from 117–27, 141
- universities and 29, 38–9, 330, 332
- Patten, C. 57
- Pavitt, K. 324
- Penn, M. 66
- Penrose, E. 111, 114, 121, 135–6, 315
- 'per use' fee system 256
- performers' rights 61–2
- personnel mobility, between DKPTO and firms 191, 199–200, 205
- Pharmaceutical Industry Association 76
- pharmaceuticals/drugs 38, 150, 262
 - anti-retroviral drugs *see* anti-retroviral drugs
 - continuation patents 225–8, 231, 234, 235
 - impact of TRIPS Agreement 70–105
 - changes in international legal system 71–84
 - patenting drugs 72–3
 - see also* biotechnology
- physical property rights (PPRs) 320–21
- physics 231, 234
- Pigou, A.C. 118
- plagiarism 259–60
- Plant, A. 114, 119–20, 122, 125, 128
- Podolny, J. 287, 290, 294, 296
- Poisson model 230
- Polanyi, M. 18, 26, 27
- policy goals *see* rationales for IPRs
- political expediency 117, 127, 133, 141
- Polygram 50
- Popper, K. 24
- Porter, R. 31
- positive theory of the social contract 113, 139
- Posner, R. 125
- power
 - corporate domination and private power 49–60
 - acquisition of private power 49–55
 - significance of private power 55–60
 - exponentiality of 54–5
 - power centrality index 295
 - practical payoffs 18, 19, 19–20
 - practice, understanding and 21–5
 - pre-issue secrecy 216, 219–21, 221–2
 - pre-qualification of ARVs 94, 95–6
 - prestige status 279, 294–301
 - Price, D. 26
 - prices of ARVs 87, 88, 91, 92, 93, 98–9
 - private institutions 9, 243–77
 - analytical framework 246–8
 - benefits from collectivization 254–5
 - factors favouring recourse to 258–65
 - mitigating effect 255–8
 - public vs private governance trade-off 263–5
 - specialized and generic institutions 266–8
 - private power *see* power
 - private sector
 - interdependence with public sector 55
 - role of public institutions in knowledge spillover to/within 136–8
 - privatization of scientific commons 3, 17–18, 21, 31
 - privileges
 - patent 314
 - rights vs 113–14
 - process innovations 156
 - process patents 231, 234
 - production rights 10, 130
 - prohibition of use 262–3
 - pro-IP era 313, 315–16, 317
 - propeller design 34, 38
 - property approach 318–21
 - prospect theory 318, 319
 - protection diffusion dilemma 253
 - prototype technologies 25
 - public display 261–2
 - public domain 137
 - copyright and loss of the commons 57–9
 - protecting 60–64

- public goods 28–9
- public health *see* AIDS/HIV
- public institutions 9, 243–77
- analytical framework 246–8
 - incomplete setting of IPRs 249, 250–53
- public vs private governance trade-off 263–5
- role in knowledge spillover to/within private sector 136–8
- specialized and generic institutions 266–8
- public interest right 63–4
- public laboratories 37–42
- public sector/private sector interdependence 55
- ‘Public Sector Intellectual Property Resource for Agriculture’ 40
- public support for science 20–21, 26–32
- publication 156, 166
- university innovation system 330–31
- publishing industry 57
- ‘pure ideas’ 129
- purified natural substances 33, 35
- Rai, A. 41
- Ranbaxy 93, 94, 100
- rationales for IPRs 5–6, 109–47
- economic rationales for a patent system 317–23
- increased information spillover 133–9, 141
- industrial development from patents 127–33, 141
- social benefits from patents 117–27, 141
- social contract theory 112–17, 141
- typology of rationales 139–42
- RCA/Columbia 51
- regional IPR agreements *see* Bangui Agreement
- Reichman, J. 75
- Reitzig, M. 227
- relational transfer of knowledge 184–5, 199
- ‘Republic of Science’ 18, 26
- research, scientific *see* science
- research and development (R&D) 315, 335
- duplication 323
 - measuring results of R&D staff 154, 162
 - military innovation systems 332–3 and patenting 117
 - research exemptions 35–7, 42
 - research organizations 36–7
 - research tools 32–3, 39–40
 - resource allocation
 - incentives and efficient 125–7
 - science 18, 19, 27
 - resource constraints 171
 - Retrovir 88, 89
 - revenue collection 255–6, 257–8, 264, 265, 268
 - see also* licensing
 - Revised Bangui Agreement 1999 78, 82–4, 100
 - rewards 114–16
 - Rice, M.P. 151
 - rights
 - natural 112–17, 141
 - vs privileges 113–14
 - ‘risk bearer’ system 257–8
 - risk management 257–8
 - Rivera-Batiz, L. 131, 134–5
 - Rivette, K.G. 122, 123, 129, 153, 154
 - Rogers v. Koons* 62
 - Romer, P. 131, 134–5
 - Rosenberg, N. 23
 - Ross, D. 117
 - royalties 152–3, 160, 163, 170, 262–3
 - as social costs 124
 - royalty collection societies 258
 - SACEM 257, 258, 261, 266, 272–3, 274
 - Saint Paul, G. 269
 - sales tax 320
 - Samuelson, P. 316
 - Saquinavir 97
 - Say, J.-B. 117
 - scarcity, creation of 125–6
 - Schankerman, M. 155, 172
 - Scherer, F.M. 72, 74, 116, 117, 120, 124
 - Schumpeter, J. 21–2
 - Schumpeterian theory of the innovator’s head-start profit 116–17
 - science 2–3, 17–45
 - co-evolution of practice and understanding 21–5

- economic rationale of organizing 133–9, 141
 governance of public science 20–21, 26–32
 importance of protecting the scientific commons 32–42
 patent law 33–7
 universities 37–42
 scientific controversies 30
 scientific papers 284
 second-line treatments 94, 97
 ‘secondhand’ patent applications 229, 235
 secrecy 156, 166–7, 193
 continuation procedure 216, 219–21, 221–2
 sectoral innovation systems 324, 326–7
 Sell, S. 47, 55, 113–14
 self-citation ratio 231, 233
 semiconductors 23, 316
 continuation patents 228–30, 234, 235
 knowledge networks 291–301, 302, 303–5
 Sened, I. 113
 Senegal 88
 serendipity 18
 serial prosecution 227
 servile copies 259–60
 Shockley, W.B. 23
 signals, strategic 152, 153, 160–61, 163, 171
 Simon and Schuster 57
 small high-tech firms 6–7, 148–76
 empirical data 157–9
 literature review 149–56
 patent demotivations 154–6, 162–7, 168, 172
 patent motivations 151–4, 159–62, 163, 167–70, 170–72
 results of empirical study 159–67
 small high-tech projects 322
 Smiers, J. 49, 62
 Smith, A. 117, 131
 social benefits from patents 117–27, 141
 social contract theory 112–17, 134, 135–6, 141
 IPR system rewards all novel technological ideas equally 115–16
 reward and value created by inventor 115
 rights vs privileges 113–14
 Schumpeterian theory of innovator’s head-start profit 116–17
 social origin of inventions 114–15
 social costs
 of broad patent scope 124
 royalties as 124
 social network theory 183–4
 social origin of inventions 114–15
 software 316
 continuation patenting 229
 open source 269, 322, 329
 small high-tech firms and patenting 150, 157–70, 170, 171–2
 Software Publishing Association 260
 Sony Corporation 50
 Sorenson, O. 183
 South Africa 76
 Spain 51
 Special 301 watch list 47
 specialization
 institutions 247–8, 266–8, 269–70
 nations and products produced 189
 spillovers
 from industrial R&D 28
 knowledge spillovers from patenting process 7–8, 12, 136–7, 179–214
 rationale for IPR 133–9, 141
 stakeholders in IPR system 13
 Stanford University 34, 38
 start-up firms 322
 static efficiency argument 125
 statutory licences *see* compulsory licensing
 Stavudine 89, 94, 95, 96
 Steinmueller, E. 150–51
 stem cell patents 41
 Stiglitz, J.E. 185
 Stokes, D. 20
 strategic alliances 280
 strategic signals 152, 153, 160–61, 163, 171
 streptomycin 38
 strong patent portfolio 153, 160
 strong ties 184
 Stuart, T. 183, 287, 290, 293
 submarine patenting 8–9, 12, 216–18, 221, 234–5, 236

- Sub-Saharan Africa 4–5, 70–105
 scale of AIDS/HIV pandemic 84–6
 supply of anti-retroviral drugs 84–98
 supply-side competition 98–9
 Switzerland 325, 326
- tacit knowledge 184, 187, 199
- Tankoano, A. 78
- tariff protection analogy debate 131–3
- Taussig, F.W. 118
- technical system 324
- technological crowding 279, 293, 294–301
- technological followers 297, 298–301, 302
- technological interdependence 114–15
- technological leaders 296–301, 302
- technological niche overlap 289, 293–4, 300–301
- technological region occupied by a patent holder, avoiding 126
- technological system 324
- technological trajectories, arbitrary 122
- technology 2–3, 335
 brokers of new technology 296–301, 302
 copyright and private power 52–4
 development too rapid for patenting 156, 166, 168
 economic rationale of organizing 133–9, 141
 new and continuation process 222
 science and 18, 19, 19–20, 21–5
- technology transfer 39
- Teece, D. 120, 150
- telecommunications 316
 small high-tech firms and patenting 150, 157–70, 170, 172
- Texas Instruments 153
- textiles 231, 234
- Thailand 86
- t'Hoen, E. 89
- 'Three by Five' (3x5) Initiative 94
- Time Warner Entertainments Company LP v. Channel 4 Television Corporation plc* 62
- Time Warner Inc. 50
- Towse, R. 48, 49, 51
- trade
 free trade 131–2
 incentive to disclose ideas in 134–5
 trade privileges 314
- Trade Related Aspects of Intellectual Property Rights (TRIPS)
 Agreement 2, 55, 61, 110, 133, 244
 commodification of creativity 47–8
 and hierarchy of international agreements 99–100
 impact on healthcare in developing countries 4–5, 70–105
 changes in international legal situation 71–84
 impact of TRIPS on Bangui Agreement 78–84
 public health conflict 73–6
 supply of ARVs in Sub-Saharan Africa 84–98
- trade rights 10, 130
- trade secrets 328
- trademarks 14, 167, 328
- traditional cultural expressions 132
- traditional knowledge 132
- Trajtenberg, M. 138, 183, 233, 281
- transaction costs 119, 120
 rationale for IPR system 139
- transactional transfer of knowledge 184–5, 199
- transformation of knowledge 187
- transmission of knowledge 182–6, 199, 205–8
- 'transparent medium' system 257–8
- Traoré, V. 91
- 'TRIPS plus' 4, 78, 82–4, 100
- typology of IPR rationales 139–42
- UNAIDS 90
- uncertainty 118–20
- understanding, practice and 21–5
- uniformity 138–9
- United Kingdom (UK) 51, 56–7, 326
 governance of public science 26–7
 public interest right 63–4
- United Nations 89
- United States (US) 315, 326, 332
 American Inventors Protection Act 1999 (AIPA) 236
 Bayh-Dole Act *see* Bayh-Dole Act
 companies and knowledge networks 297, 298, 299, 302
 continuation patents 8–9, 12, 215–39
 counterbalancing rights 61

- Digital Millennium Copyright Act 52–3
- Doha Declaration veto 77
- Drug Price Competition and Patent Term Restoration Act 1984 227
- governance of public science 26–7
- Hatch Act 1887 208
- links between patent examiners and judges 267
- Morill Act 1862 208
- Omnibus Trade and Competitiveness Act 1988 47
- Patent Act 1952 220
- 1995 changes 218, 221–2, 227–8, 229, 234–5
- public and private institutions 245, 252, 258
- IPR system compared with France's 266–70
- technology and copyright 52–4
- Trade Act 1974 47
- TRIPS Agreement 47, 55, 61
- universities and scientific commons 37–42
- video market 51
- United States Patent and Trademark Office (USPTO) 208
- continuation patents 8–9, 215–39
- Universal Copyright Convention 244
- Universal Studios v. Corley* 63
- universalism 30
- universities 29, 208
- policies and research findings 37–42
- research exemptions 36–7, 42
- university innovation systems 324, 329–32
- Uruguay Round 2, 4, 74, 110
- user behaviour 259–60
- user rights, copyright and 48
- 'usus' rights 250, 264, 265, 268
- utilitarian classical economics 117–18
- utility 35
- utilization ratio of patents 323
- value
- created by inventor 115
- indicators of 152, 153–4, 161–2, 163
- Venice 314
- venture capitalists 120–21
- Verspagen, B. 286
- Viacom Inc. 50
- video market 51–2
- Videx 88, 89
- Vincenti, W. 24, 34
- Vinding, A. 184
- von Hippel, E. 323
- Waldron, J. 46, 58, 59, 60
- Walsh, J. 25, 32–3
- Walt Disney Prods v. Air Pirates* 58
- Warner Home Video 51
- Watal, J. 72, 74
- WEA 50
- weak ties 184
- Williamson, O.E. 247, 248, 266
- Willoughby, K. 151
- Winter, S. 25, 124, 126, 136
- Wisconsin, University of 41
- World Bank 89
- World Commission on Culture and Development 59–60, 64
- World Health Organization (WHO) 89, 92
- 3x5 Initiative 94
- treatment guidelines for AIDS/HIV 94, 95–6, 97
- World Intellectual Property Organisation (WIPO) 73
- Performers and Phonograms Treaty 1996 61–2, 63
- World Trade Organisation (WTO) 73–4, 244
- implementation of Doha Declaration 77–8, 100–101
- TRIPS *see* Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement
- World War II 26, 117
- Wyatt, S. 152, 153, 154, 159
- Zerit 88, 89
- Zhang, S. 73, 74
- Zidovudine 89, 94, 95, 96
- Ziedonis, R.H. 235
- Zigani, W. 91
- Ziman, J. 18, 24